Skip to content
drillr.ai

PCRX

Pacira BioSciences, Inc.

NASDAQ · USHealthcareDrug Manufacturers - Specialty & Generic
$25.35-1.02%

Price as of Jul 20, 2026

PCRX news

Pacira BioSciences, Inc. news

A server-rendered, paginated timeline of the latest available company news.

  1. Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    BRISBANE, Calif., July 08, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies to transform the lives of patients, today announced the granting of inducement awards on July 2, 2026 to ten new employees under Pacira’s Amended and Restated 2014 Inducement Plan (the “Inducement Plan”) as a material inducement to each employee’s entry into employment with the company. In accordance with Nasdaq Listing Rule 563

    Globe Newswire ·

  2. Pacira BioSciences Announces Stockholders Have Elected All Three of the Company's Director Nominees at Annual Meeting

    Pacira BioSciences Announces Stockholders Have Elected All Three of the Company's Director Nominees at Annual Meeting PR Newswire BRISBANE, Calif., June 9, 2026 BRISBANE, Calif., June 9, 2026 /PRNewswire/ -- Pacira BioSciences, Inc. (Nasdaq: PCRX) (the "Company" or "Pacira"), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced that based on the preliminary results of its 2026 Annual Meeting of Stockholders

    PR Newswire ·

  3. Pacira BioSciences Reminds Stockholders to Vote the BLUE Proxy Card "FOR" the Election of the Company's Highly Qualified Nominees Ahead of its Annual Meeting

    Pacira BioSciences Reminds Stockholders to Vote the BLUE Proxy Card "FOR" the Election of the Company's Highly Qualified Nominees Ahead of its Annual Meeting PR Newswire BRISBANE, Calif., June 4, 2026 Election of Even a Single DOMA Nominee Would Risk Compromising Pacira's Strong Forward Momentum Leading Independent Experts ISS, Glass Lewis and Egan-Jones Agree that DOMA Representation Is Not Warranted BRISBANE, Calif., June 4, 2026 /PRNewswire/ -- Pacira BioSciences, Inc. (Nasdaq: PCRX) (th

    PR Newswire ·

  4. Pacira BioSciences Highlights Leading Independent Proxy Advisory Firm ISS' Recommendation to Vote "FOR" All of Pacira's Director Nominees

    Pacira BioSciences Highlights Leading Independent Proxy Advisory Firm ISS' Recommendation to Vote "FOR" All of Pacira's Director Nominees PR Newswire BRISBANE, Calif., June 1, 2026 ISS Concludes "There is a Compelling Reason to Support all Management Nominees" and Notes "the Dissident Has Not Presented a Compelling Case for Change" BRISBANE, Calif., June 1, 2026 /PRNewswire/ -- Pacira BioSciences, Inc. (Nasdaq: PCRX) (the "Company" or "Pacira"), the industry leader in its commitment to deliv

    PR Newswire ·

  5. Leading Independent Proxy Advisory Firm Glass Lewis Recommends Stockholders Vote “FOR” All of Pacira’s Director Nominees

    BRISBANE, Calif., May 28, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX) (the “Company” or “Pacira”), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced that leading independent proxy advisory firm Glass Lewis & Co., LLC (“Glass Lewis”) has recommended that Pacira stockholders vote “FOR” each of Pacira’s three director nominees – Christopher Christie, Samit Hirawat, MD and Thomas Wiggans – a

    Globe Newswire ·

  6. DOMA PERPETUAL CAPITAL MANAGEMENT QUESTIONS WHY SHAREHOLDERS SHOULD VOTE TO CONTINUE WITH A BOARD THAT HAS OVERSEEN A DECADE OF VALUE DESTRUCTION

    DOMA PERPETUAL CAPITAL MANAGEMENT QUESTIONS WHY SHAREHOLDERS SHOULD VOTE TO CONTINUE WITH A BOARD THAT HAS OVERSEEN A DECADE OF VALUE DESTRUCTION PR Newswire MIAMI, May 28, 2026 PACIRA'S STOCK PRICE IS DOWN FOR EVERY RECENT PERIOD: 10 YEAR, 5 YEAR, 3 YEAR, 2 YEAR, ONE YEAR, AND YEAR-TO-DATE DOMA BELIEVES MANAGEMENT IS MISLEADING STAKEHOLDERS REGARDING ITS PATENT PROTECTION AND MINIMIZING THE POTENTIAL BUSINESS-DESTROYING CONSEQUENCES OF ANOTHER LEGAL LOSS, CONSTITUTING GROSS NEGLIGENCE DOMA

    PR Newswire ·

  7. Pacira BioSciences Mails Letter to Stockholders Reiterating Confidence in the Company’s Strategic Direction and Highly Qualified Nominees

    Clarifies DOMA’s Inaccuracies and the Reality of Pacira’ Efforts to Strengthen its Market Position Urges Stockholders to Vote “FOR” the Election of Pacira’s Highly Qualified Nominees on the BLUE Proxy Card Today BRISBANE, Calif., May 27, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX) (the “Company” or “Pacira”), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today issued the following communication wi

    Globe Newswire ·

  8. A Reno Biotech Just Rang the Nasdaq Bell — Here’s Why the Whole Regenerative-Medicine Tape Is Worth Watching

    Five companies. One overlapping story. The race to rebuild human tissue is moving from the lab into the public markets — fast. NEW YORK, May 22, 2026 (GLOBE NEWSWIRE) -- World Street Intelligence News Commentary — There are weeks when the most interesting story on Wall Street isn’t a single ticker. It’s the through-line connecting several of them. The week of May 21, 2026 was one of those weeks. A brand-new Nasdaq listing in regenerative tissue arrived in the middle of a cluster of earnings be

    Globe Newswire ·

  9. A LETTER TO PACIRA BIOSCIENCES SHAREHOLDERS FROM DOMA PERPETUAL CAPITAL MANAGEMENT LLC

    A LETTER TO PACIRA BIOSCIENCES SHAREHOLDERS FROM DOMA PERPETUAL CAPITAL MANAGEMENT LLC PR Newswire MIAMI, May 21, 2026 FRANK LEE AND THE BOARD HAVE OVERSEEN GROSS AND PERSISTENT UNDERPERFORMANCE FOR YEARS. WHY WOULD SHAREHOLDERS VOTE TO CONTINUE THIS UNRELENTING LACK OF TOTAL RETURN TO SHAREHOLDERS ("TRS"), WHILE ALLOWING MANAGEMENT AND THE BOARD TO FURTHER ENRICH THEMSELVES WITH TENS OF MILLIONS OF DOLLARS IN PAYOUTS? EXPAREL IS THE COMPANY'S CORE ASSET; WE BELIEVE BOARD MISMANAGEMENT OF TH

    PR Newswire ·

  10. DOMA Perpetual Director Nominees Send Letter to Shareholders of Pacira Biosciences

    DOMA Perpetual Director Nominees Send Letter to Shareholders of Pacira Biosciences PR Newswire MIAMI, May 20, 2026 Independent Directors, Christopher Dennis, MD, MBA, FAPA and Oliver Benton "Ben" Curtis III Outline How Their Skills and Experience Will Drive Positive Change Intend to Work Collaboratively with Incumbent Directors to Strengthen Oversight and Create Value for All Shareholders Encourage Shareholders to Support Meaningful Board Change by Voting via the WHITE Proxy Card for DOMA's

    PR Newswire ·

  11. Pacira BioSciences Files Investor Presentation Highlighting Successful Execution of its Long-Term Strategy to Drive Value for All Stockholders

    Urges Stockholders to Vote “FOR” the Election of Pacira’s Highly Qualified Nominees on the BLUE Proxy Card Today BRISBANE, Calif., May 20, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX) (the “Company” or “Pacira”), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, recently posted an investor presentation in connection with its upcoming 2026 Annual Meeting of Stockholders (the “Annual Meeting”), scheduled

    Globe Newswire ·

  12. Pacira BioSciences Sends Letter to Stockholders Reiterating Superior Qualifications of its Board Nominees

    Highlights Nominees’ Robust Skillsets and Extensive Experience in Healthcare and Biopharmaceuticals Urges Stockholders to Vote “FOR” the Election of Pacira’s Highly Qualified Nominees on the BLUE Proxy Card Today BRISBANE, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX) (the “Company” or “Pacira”), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced that it has sent a letter

    Globe Newswire ·

  13. Pacira BioSciences Mails Letter to Stockholders

    Details Success of Pacira’s 5x30 Strategy and Solid First Quarter 2026 Results  Reiterates Board’s Unanimous Recommendation that Stockholders Vote “FOR” the Election of Pacira’s Highly Qualified Nominees on the BLUE Proxy Card Today BRISBANE, Calif., May 05, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX) (the “Company” or “Pacira”), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced that i

    Globe Newswire ·

  14. Pacira BioSciences Files Definitive Proxy Materials and Mails Letter to Shareholders

    Urges Stockholders to Vote “FOR” Pacira’s Highly Qualified Nominees on the BLUE Proxy Card Today Strongly Opposes the Election of Each of DOMA’s Underqualified Nominees BRISBANE, Calif., April 28, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX) (the “Company” or “Pacira”), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced that it has filed its definitive proxy materials with the U.S. Secur

    Globe Newswire ·

  15. PharmaCorp Announces Investor Relations Agreement

    SASKATOON, Saskatchewan, April 13, 2026 (GLOBE NEWSWIRE) -- PHARMACORP RX INC. (“PharmaCorp” or the “Corporation”) (TSXV: PCRX) is pleased to announce it has entered into a public listing services agreement (the “Agreement”) with LodeRock Advisors Inc. (“LodeRock”) to provide the Corporation with investor relations services, with a primary focus on developing and executing a 12‑month investor relations strategy, advising senior management on investor‑related matters, and maintaining strong relat

    Globe Newswire ·

  16. Pacira Presents Real-World Data on EXPAREL® Showing Lower Total Healthcare Costs in Outpatient Total Hip and Knee Arthroplasty Procedures

    -- Select findings demonstrate that the use of EXPAREL(®) (bupivacaine liposome injectable suspension) in outpatient Total Hip Arthroplasty (THA) and Total Knee Arthroplasty (TKA) is associated with lower total healthcare costs over various follow-up periods — -- Reduced opioid use observed at 6 months post-surgery among Medicare Advantage patients with low back pain in THA Study -- BRISBANE, Calif., April 13, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX), the industry leade

    Globe Newswire ·

  17. Bronstein, Gewirtz & Grossman, LLC Encourages Pacira BioSciences, Inc. (PCRX) Shareholders to Inquire about Securities Investigation

    NEW YORK CITY, NY / ACCESS Newswire (https://www.accessnewswire.com/) / April 12, 2026 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Pacira BioSciences, Inc. ("Pacira" or "the Company") (NASDAQ:PCRX). Investors who purchased Pacira securities prior to August 2, 2023, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/PCRX. (https://bgandg.com/

    ACCESSWIRE ·

  18. PharmaCorp Rx Inc. To Present At The 2026 Bloom Burton & Co. Healthcare Investor Conference

    SASKATOON, Saskatchewan, April 02, 2026 (GLOBE NEWSWIRE) -- PharmaCorp Rx Inc. (“PharmaCorp” or the “Corporation”) (TSXV: PCRX) a Canadian pharmacy services and consolidation platform, announced today that it will deliver a corporate presentation at the 2026 Bloom Burton & Co. Healthcare Investor Conference on April 21, 2026, at 9:30 am ET in Toronto, Ontario. PharmaCorp senior management will also participate in one-on-one meetings during the conference. Interested parties can view the webcast

    Globe Newswire ·

  19. Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Pacira BioSciences, Inc. (PCRX) and Encourages Stockholders to Learn More About the Investigation

    NEW YORK CITY, NY / ACCESS Newswire (https://www.accessnewswire.com/) / March 26, 2026 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Pacira BioSciences, Inc. ("Pacira" or "the Company") (NASDAQ:PCRX). Investors who purchased Pacira securities prior to August 2, 2023, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/PCRX. (https://bgandg.com/

    ACCESSWIRE ·

  20. DOMA Perpetual Nominates Three Highly Qualified Candidates for the Board of Pacira BioSciences, Inc.

    DOMA Perpetual Nominates Three Highly Qualified Candidates for the Board of Pacira BioSciences, Inc. PR Newswire MIAMI, March 12, 2026 Pacira's Stock is Down 56% Over the Last Decade and Down 68% Over the Last 5 Years([i]); Under the Leadership of CEO and Board Member Frank Lee, the Stock Has Fallen 30%([ii]); The Company's Underperformance is Reflected in Consistently Missed Earnings, Continuous Lowering of Guidance, Which is Then Missed, and a Complete Lack of Combined Profitability in the Las

    PR Newswire ·